New recommendations prioritise multiparametric MRI, safer transperineal biopsy, and earlier escalation for high-risk prostate ...

Secondary endpoint data from the EMBARK trial support use of enzalutamide treatments in patients with high-risk biochemically recurrent prostate cancer.

Patients who developed biochemical recurrence had a higher PSA at diagnosis, more advanced pT stages, a higher rate of pN1 stage disease, a higher rate of R1 or Rx resection, and a higher rate of ...

XTANDI is now the first and only novel hormone therapy available for the treatment of high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer in the European Union (EU) XTANDI ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

What happens if PSA levels start rising after surgery or radiation for prostate cancer? Up to a third of men treated for the disease will eventually confront this problem. If there's no accompanying ...

Phase II Study of Paclitaxel Plus Gemcitabine in Refractory Germ Cell Tumors (E9897): A Trial of the Eastern Cooperative Oncology Group PURPOSE: To assess the effect of nerve-sparing (NS) radical ...

The postsurgical combination of androgen deprivation therapy and Erleada has shown promising results in prostate cancer. Postsurgical treatment with androgen deprivation therapy and Erleada ...

One of 51 (2.0%) patients in the ultra-early salvage ADT group developed biochemical recurrence, compared with 12 of 70 (17.1%) patients in the early salvage ADT group (Figure 1). Univariate analysis ...

SAN ANTONIO -- More than 2 years after treatment, no patient with high-risk prostate cancer had a confirmed biochemical recurrence after receiving postoperative apalutamide (Erleada) and androgen ...

- If approved, XTANDI would become the first and only NHT treatment available for metastatic and high risk biochemical recurrent non-metastatic hormone sensitive prostate cancer patient populations in ...